Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis.
作者信息
Hussain Amara S, Hari Parameswaran, Brazauskas Ruta, Arce-Lara Carlos, Pasquini Marcelo, Hamadani Mehdi, D'Souza Anita
机构信息
Department of Medicine.
Medical College of Wisconsin, Institute of Health and Society, Milwaukee, Wisconsin.
出版信息
Am J Hematol. 2015 Nov;90(11):E212-3. doi: 10.1002/ajh.24176. Epub 2015 Oct 6.
Abstract
摘要
相似文献
1
Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis.
Am J Hematol. 2015 Nov;90(11):E212-3. doi: 10.1002/ajh.24176. Epub 2015 Oct 6.
2
Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis.
Eur J Cancer. 2017 May;76:183-187. doi: 10.1016/j.ejca.2017.02.004. Epub 2017 Mar 20.
3
Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
Am J Hematol. 2014 Dec;89(12):1132-40. doi: 10.1002/ajh.23828.
4
Light chain amyloidosis 2012: a new era.
Br J Haematol. 2013 Mar;160(5):582-98. doi: 10.1111/bjh.12191. Epub 2013 Jan 7.
5
Total Artificial Heart Implantation as a Bridge to Heart Transplantation in an Active Duty Service Member With Amyloid Cardiomyopathy.
Mil Med. 2017 Mar;182(3):e1858-e1860. doi: 10.7205/MILMED-D-16-00122.
6
A retrospective analysis of treatment outcomes in 45 patients with cardiac light-chain amyloidosis: a single-center experience in Japan.
Int J Hematol. 2020 Jun;111(6):803-811. doi: 10.1007/s12185-020-02835-8. Epub 2020 Feb 4.
7
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).
Haematologica. 2014 Sep;99(9):1479-85. doi: 10.3324/haematol.2014.104109. Epub 2014 May 23.
8
Isolated cardiovascular involvement in light chain amyloidosis.
BMJ Case Rep. 2020 Apr 6;13(4):e233227. doi: 10.1136/bcr-2019-233227.
9
Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial.
Circulation. 2022 Jan 4;145(1):8-17. doi: 10.1161/CIRCULATIONAHA.121.055953. Epub 2021 Sep 10.
10
Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib.
Blood Cancer J. 2017 Jun 16;7(6):e570. doi: 10.1038/bcj.2017.47.
引用本文的文献
1
Prevalence of Atrial Fibrillation and Intervention Therapy in Cardiac Amyloidosis.
Rev Cardiovasc Med. 2025 May 22;26(5):37064. doi: 10.31083/RCM37064. eCollection 2025 May.
2
Circulating Biomarkers for Cardiotoxicity Risk Prediction.
Curr Treat Options Oncol. 2021 Apr 17;22(6):46. doi: 10.1007/s11864-021-00845-0.
3
Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change.
Blood Cancer J. 2021 Feb 1;11(2):29. doi: 10.1038/s41408-021-00412-8.
4
Ubiquitin‑proteasomes are the dominant mediators of the regulatory effect of microRNA‑1 on cardiac remodeling after myocardial infarction.
Int J Mol Med. 2019 Nov;44(5):1899-1907. doi: 10.3892/ijmm.2019.4330. Epub 2019 Sep 4.
5
Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis.
JACC Basic Transl Sci. 2019 Jun 24;4(3):438-448. doi: 10.1016/j.jacbts.2019.02.002. eCollection 2019 Jun.
6
Recent advances in understanding and treating immunoglobulin light chain amyloidosis.
F1000Res. 2018 Aug 29;7. doi: 10.12688/f1000research.15353.1. eCollection 2018.
本文引用的文献
1
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).
Haematologica. 2014 Sep;99(9):1479-85. doi: 10.3324/haematol.2014.104109. Epub 2014 May 23.
2
Ventricular fibrillation after bortezomib therapy in a patient with systemic amyloidosis.
Hematol Rep. 2013 Sep 16;5(3):e12. doi: 10.4081/hr.2013.e12. eCollection 2013.
3
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.
QJM. 2011 Nov;104(11):957-70. doi: 10.1093/qjmed/hcr105. Epub 2011 Jul 13.
4
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs.
Am J Hematol. 2010 Oct;85(10):757-9. doi: 10.1002/ajh.21822.
5
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.
J Clin Oncol. 2010 Feb 20;28(6):1031-7. doi: 10.1200/JCO.2009.23.8220. Epub 2010 Jan 19.
6
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.
Blood. 2009 Aug 20;114(8):1489-97. doi: 10.1182/blood-2009-02-203398. Epub 2009 Jun 4.
Zotero 插件